Boston Scientific touts 3-year Alair follow-up study results

Boston Scientific (NYSE:BSX) today released 3-year follow-up cohort results from the post-FDA approved PAS2 clinical trial of its Alair system designed for bronchial thermoplasty to treat severe persistent asthma, touting reduced severe asthma attacks, hospitalizations and ER visits.

Results from the trial were recently published in the European Respiratory Journal, the Marlborough, Mass.-based company said.

The PAS2 trial is an open-label study which enrolled patients at 27 North American centers, with 95% of the recruited patients considered severe asthmatics. Boston Scientific said that data from the cohort corroborated earlier data from the AIR2 trial of the device and validate the results in the real-world.

“The results of the PAS2 study confirm that treatment with BT has an enormous and positive impact in every day clinical practice and may relieve some of the burden that adults with severe asthma face. We will continue to work to make sure that patients have access and coverage for this established, important treatment that has been shown to improve asthma-related quality of life,” Boston Scientific endoscopy division prez Art Butcher said in a prepared statement.

Data from the trial indicated a 34% reduction in severe asthma-related exacerbations, an 8% reduction in hospitalizations and 16% reduction in emergency room visits. Patients in the trail also reported a 9% decrease in the need to use daily maintenance oral corticosteroids.

“The PAS2 study confirms that BT is an effective, durable and safe treatment in severe asthmatics that have poorer asthma control at baseline compared to patients evaluated in previous clinical trials, such as AIR2. The PAS2 study is the 1st large-scale, prospective study of BT performed in a post-market setting and validates the positive results from the AIR2 trial,” principal investigator Dr. Geoffrey Chupp of the Yale Center for Asthma and Airways Disease said in a press release.

Last week, Boston Scientific said it launched operations at its Penang, Malaysia-based facilities, the medical device giant’s 1st Asian manufacturing facility.

The post Boston Scientific touts 3-year Alair follow-up study results appeared first on MassDevice.

from MassDevice http://ift.tt/2y9suNg